WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013116948) INDOLIZINE DERIVATIVES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/116948    International Application No.:    PCT/CA2013/050104
Publication Date: 15.08.2013 International Filing Date: 08.02.2013
IPC:
C07D 471/04 (2006.01), A61K 31/437 (2006.01)
Applicants: PERAMPALLI NEKKAR, Praveen, Rao [CA/CA]; (CA).
NABIL KABIR, Saad [CA/CA]; (CA)
Inventors: PERAMPALLI NEKKAR, Praveen, Rao; (CA).
NABIL KABIR, Saad; (CA)
Agent: SILVER, Gail C.; Borden Ladner Gervais LLP World Exchange Plaza 100 Queen Street, Suite 1300 Ottawa, Ontario K1P 1J9 (CA)
Priority Data:
61/633,325 09.02.2012 US
Title (EN) INDOLIZINE DERIVATIVES
(FR) DÉRIVÉS D'INDOLIZINE
Abstract: front page image
(EN)Disclosed herein are indolizine compounds of general formula I, wherein R1-R7, X and Y are as disclosed in the application, useful as inhibitors of lipoprotein associated phospholipase A2 (Lp-PLA2) and/or 15-lipoxygenase ( 15-LOX), as well as methods of preparation and use thereof, and compositions thereof Advantageously, certain compounds disclosed herein are capable of inhibiting both Lp-PLA2 and 15-LOX. Accordingly, provided herein are methods of inhibiting one or both of Lp-PLA2 and 15-LOX, and methods of treating diseases or conditions associated with Lp-PLA2 and/or 15-LOX.
(FR)L'invention concerne des composés d'indolizine de formule générale I, dans laquelle R1 à R7, X et Y sont tels que décrits dans la demande, utiles en tant qu'inhibiteurs de phospholipase A2 associée à la lipoprotéine (Lp-PLA2) et/ou de lipoxygénase 15 (15-LOX), ainsi que des procédés de préparation et d'utilisation associés, et des compositions associées. Avantageusement, certains composés décrits dans le présent document sont capables d'inhiber à la fois Lp-PLA2 et 15-LOX. L'invention concerne ainsi des procédés d'inhibition de Lp-PLA2 et/ou 15-LOX, et des procédés de traitement de maladies ou de troubles associés avec Lp-PLA2 et/ou 15-LOX.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)